{"id":"W4410840498","doi":"10.1016/j.esmoop.2025.105065","title":"Health-related quality of life analysis of the LEAP-002 study of lenvatinib plus pembrolizumab versus lenvatinib as first-line treatment for advanced hepatocellular carcinoma","year":2025,"lang":"en","type":"article","venue":"ESMO Open","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Eli Lilly Japan; Chugai Pharmaceutical; Genentech; Eisai Canada; Otsuka Pharmaceutical; Merck Sharp and Dohme; Ono Pharmaceutical; Eisai; Sanofi; Exelixis; Moderna; F. Hoffmann-La Roche; Taiho Pharmaceutical; Boston Scientific Corporation; Ipsen; BeiGene; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Lenvatinib; Pembrolizumab; Hepatocellular carcinoma; Medicine; Oncology; Internal medicine; Cancer; Sorafenib; Immunotherapy","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009605438,0.00104627,0.00163331,0.0004436492,0.0002659545,0.00116034,0.0007099353,0.0006897138,0.00316316],"category_scores_gemma":[0.00595699,0.0004513683,0.00202168,0.0006087192,0.0005257038,0.0009873356,0.000986386,0.001859235,0.0003687271],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005864098,"about_ca_system_score_gemma":0.0007331724,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004073389,"about_ca_topic_score_gemma":0.0003832026,"domain_scores_codex":[0.9959899,0.003083292,0.0001328447,0.0003234929,0.000304783,0.0001657151],"domain_scores_gemma":[0.996472,0.001323475,0.0009070942,0.0003465979,0.0002603763,0.000690543],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7793491,0.006893506,0.1634345,0.0009890647,0.01330846,0.0002168414,0.0002450307,0.003698895,0.003882858,0.0001929669,0.001775119,0.02601363],"study_design_scores_gemma":[0.1387304,0.2102514,0.6260698,0.0001401036,0.007617263,0.0005197074,0.0002996103,0.009052982,0.002042098,0.0005286112,0.004633172,0.0001147571],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9963729,0.001015774,0.0003161876,0.0001223,0.00002326485,0.000339801,0.001204306,0.00001039755,0.0005951296],"genre_scores_gemma":[0.9949598,0.000220777,0.0003558408,0.0001281952,0.00004458965,0.0009422142,0.002826248,0.000006177735,0.0005161179],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009605438,"threshold_uncertainty_score":0.05079901,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1833503997129842,"score_gpt":0.37988705921614,"score_spread":0.1965366595031558,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}